Chronic skin ulcers
Reponex has formulated two gels (topical medicinal products), one with molgramostim alone and another with the addition of other wound healing agents, sucralfate and hyaloronan. A third medicinal product combines molgramostim and fosfomycin for grossly infected chronic wounds. A randomized placebo controlled clinical phase II trial on the first product is underway in collaboration with Bispebjerg Hospital. Subsequent trials on the two other products will be conducted.
Chronic skin wounds or ulcers are typically associated with diabetes, venous insufficiency, local pressure (e.g. bedsores) or ischemia (insufficient blood flow). Taken together, chronic wounds and ulcers affect more than 1% of the industrialized world’s population. In the USA alone, they affect up to 6 million people, and at least as many in the EU.